60 Degrees Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
60 Degrees Pharmaceuticals, Inc. filed this Form 8-K on November 3, 2023, reporting an event dated November 2, 2023. The filing concerns the continued Nasdaq listing status of the company’s common stock and warrants. It does not report quarterly or annual operating results.
Financial and operating metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material changes versus the prior comparable period
- Nasdaq notified the company that its common stock failed to maintain the required minimum closing bid price of $1.00 per share for 30 consecutive business days, from September 19 through November 1, 2023.
- The deficiency relates to Nasdaq Listing Rule 5550(a)(2), the Bid Price Rule.
- The notice has no immediate effect on the listing of the company’s common stock or warrants. Both continue to trade on the Nasdaq Capital Market under SXTP and SXTPW, respectively.
Guidance, outlook, risks, contingencies, and unusual items
- The company received an initial 180-calendar-day compliance period ending April 30, 2024, to regain compliance.
- If eligible, the company may receive an additional 180-day compliance period, subject to meeting applicable market value and other initial Nasdaq listing requirements and providing written notice of its intent to cure the deficiency, potentially through a reverse stock split.
- If the company fails to regain compliance during the available compliance period, its common stock and warrants may be delisted. The company may appeal a delisting determination to a Nasdaq hearings panel.
- Management stated that it is evaluating options to regain compliance, but provided no specific remediation plan or assurance of success.
Key facts investors should verify
- Whether the company regained compliance with Nasdaq’s $1.00 minimum bid price requirement by April 30, 2024 or during any subsequent compliance period.
- Whether a reverse stock split or another corporate action was implemented.
- Whether the company satisfied Nasdaq’s other continued-listing requirements.
- Any subsequent Nasdaq delisting notice, hearing decision, or change in the trading status of SXTP and SXTPW.